Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rosemarie de Haan
Observed names:
R. De Haan,
R. de Haan,
de Haan, Rosemarie
Institution:
The Netherlands Cancer Institute
Observed institutions:
Amsterdam UMC Location University of Amsterdam,
The Netherlands Cancer Institute,
University of Amsterdam
ORCID:
0000-0002-3220-3190
Observed ORCID:
0000-0002-3220-3190
OpenAlex ID:
A5060740359
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
2015
·
Caroline V.M. Verhagen
, Rosemarie de Haan
, et al.
·
Radiotherapy and Oncology
·
122
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2020
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
·
Clinical Cancer Research
·
66
PDF
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
2019
·
R. de Haan
, E. van Werkhoven
, et al.
·
BMC Cancer
·
52
PDF
Retinal Arteriolar Geometry is Associated with Cerebral White Matter Hyperintensities on Magnetic Resonance Imaging
2010
·
Fergus N. Doubal
, Rosemarie de Haan
, et al.
·
International Journal of Stroke
·
42
PDF
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
2017
·
Rosemarie de Haan
, Dick Pluim
, et al.
·
Radiotherapy and Oncology
·
25
PDF
Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples
2020
·
Erik van Werkhoven
, Samantha Hinsley
, et al.
·
BMC Medical Research Methodology
·
20
PDF
Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma
2023
·
Arash Navran
, Abrahim Al-Mamgani
, et al.
·
Clinical and Translational Radiation Oncology
·
14
PDF
OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent
2015
·
R. De Haan
, C.V.M. Verhagen
, et al.
·
Radiotherapy and Oncology
·
2
888P Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
2023
·
M. Verheij
, A. Navran
, et al.
·
Annals of Oncology
·
1
PDF
Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites
2016
·
M. Verheij
, R. De Haan
, et al.
·
Radiotherapy and Oncology
·
1
PDF
Supplementary File 8: Olaparib Pharmacokinetics. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
PDF
Supplementary File 4: Adverse Events. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
PDF
Supplementary File 3: Dose Limiting Toxicity. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
PDF
Supplementary File 6: Pulmonary Function Tests and Pulmonary Adverse Events by Treatment Arm. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
Supplementary File 7: Loco-regional control and survival. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
Supplementary File 5: Esophageal Adverse Events. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
Supplementary File 2: Treatment details. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
Supplementary File 1: Supplementary Methods. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
PDF
Supplementary File 2: Treatment details. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
PDF
Data from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
2023
·
Rosemarie de Haan
, Michel M. van den Heuvel
, et al.
OC-0438: Clinical pharmacodynamics support biological effectivity of low dose olaparib as radiosensitizer
2020
·
R. De Haan
, D. Pluim
, et al.
·
Radiotherapy and Oncology
OC-0692: Phase 1 study of olaparib as radiosensitizer for locally advanced non-small cell lung cancer
2020
·
R. De Haan
, J. Van Diessen
, et al.
·
Radiotherapy and Oncology
Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
2019
·
Rosemarie de Haan
, Dick Pluim
, et al.
·
Molecular Cancer Therapeutics
OC-0418 Residual misalignment of supraclavicular lymph nodes for NSCLC patients, to determine GTVPTV margin
2019
·
J. Stam
, S. Gerrets
, et al.
·
Radiotherapy and Oncology
PDF
351 Sensitive pharmacodynamic assessment of PARP inhibitors for individualized treatment in clinic
2015
·
R. De Haan
, D. Pluim
, et al.
·
European Journal of Cancer
Show more works
View as search
Works count:
28
Citation count:
345
H-index:
7
I10-index:
7
Year
Topic
Type